NCT00054639 - Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Cutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSmall Intestine LymphomaSplenic Marginal Zone LymphomaTesticular LymphomaWaldenström Macroglobulinemia

Interventions

BIOLOGICAL

oblimersen sodium

Given IV

BIOLOGICAL

rituximab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH